[go: up one dir, main page]

US20140206631A1 - Cardiac Glycoside Analogs in Combination with Emodin for Cancer Therapy - Google Patents

Cardiac Glycoside Analogs in Combination with Emodin for Cancer Therapy Download PDF

Info

Publication number
US20140206631A1
US20140206631A1 US14/034,423 US201314034423A US2014206631A1 US 20140206631 A1 US20140206631 A1 US 20140206631A1 US 201314034423 A US201314034423 A US 201314034423A US 2014206631 A1 US2014206631 A1 US 2014206631A1
Authority
US
United States
Prior art keywords
emodin
digoxin
combination
approximately
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/034,423
Inventor
Nadav Shraibom
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sirbal Ltd
Original Assignee
Sirbal Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sirbal Ltd filed Critical Sirbal Ltd
Priority to US14/034,423 priority Critical patent/US20140206631A1/en
Assigned to SIRBAL LTD. reassignment SIRBAL LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SHRAIBOM, NADAV
Publication of US20140206631A1 publication Critical patent/US20140206631A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
    • A61K36/704—Polygonum, e.g. knotweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
    • A61K36/708—Rheum (rhubarb)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates generally to cancer therapeutics. More specifically it concerns the use of cardiac glycosides such as Digoxin and Quabain in combination with Emodin and its analogs for the treatment of cancer.
  • Emodin (1,3,8-trihydroxy-6-methylanthraquinone) and aloe-emodin, 1,8-dihydroxy-3-hydroxymethyl-9,10-anthracenedione as shown a chemotherapeutic activity in vitro and in animal models for the treatment of various types of cancers, including bladder cancer,3 lung cancer,4 and hepatoma.5, and leukemia.
  • Aloe-emodin is a natural anthraquinone compound that is present in some traditional medicinal plants such as Rhei Rhizoma and Rheum palmatum, Interestingly, aloe-emodin has been found to have lesser cytotoxicity towards the normal human cells.6
  • Plant-derived cardiac glycosides such as digoxin are used for the treatment of congestive heart failure and other cardiac disorders (1). Their main pharmacologic actions are mediated through inhibition of the sodium pump, Na+- and K+-dependent ATPase (NKA) 1 (EC 3.6.3.9) (2).
  • NKA Na+- and K+-dependent ATPase
  • NKA a ubiquitous membrane cationic transporter protein, controls normal membrane potential in all eukaryotic cells by maintaining high K+ and low Na+ concentrations. It consists of a catalytic subunit and a B glycoprotein subunit (3).
  • FIG. 1 illustrates the effect of on proliferation of digoxin, Emodin, and their combination on NB4 leukemic cells.
  • FIG. 2 illustrates the effect of on proliferation of digoxin, Emodin, and their combination on HL-60 leukemic cells.
  • FIG. 3 illustrates the effect of on proliferation of digoxin, Emodin, and their combination on Jurkat T cell leukemic cells.
  • FIG. 4 illustrates the effect of on proliferation of digoxin, Emodin, and their combination on HT29 colon cancer cells.
  • FIG. 5 illustrates the effect of proliferation of digoxin, Emodin, and their combination on PC3 prostate tumor cells.
  • FIG. 6 illustrates the effect of proliferation of Digoxin, Emodin and their combination on MDA 435 Breast Cancer cells.
  • FIG. 7 illustrates the effect of proliferation of Digoxin, Emodin and their combination on MDA 435 cell lines of Melanoma and Breast Cancer.
  • FIG. 8 illustrates the effect of proliferation of Digoxin, Emodin and their combination on Heparanase activity.
  • FIG. 9 illustrates the effect of proliferation of Digoxin, Emodin and their combination on HMVEC activity.
  • FIGS. 10-11 illustrates the effect of proliferation of Digoxin, Emodin and their combination on NB-4 Cell Line for AML (Acute Milo Leukemia).
  • FIG. 12 illustrates the effect of proliferation of Digoxin, Emodin and their combination on HL-60 Cell Line.
  • FIG. 13 illustrates the effect of proliferation of Digoxin, Emodin and their combination on Jurkat cell line.
  • FIG. 14 illustrates the effect of proliferation of Digoxin, Emodin and their combination on HT-29 cell line.
  • MICHAEL J. KEATING et al., Biology and Treatment of Chronic Lymphocytic Leukemia, American Society of Hematology, Hematology 2003, 153-175;
  • CLL Chronic Lymphocytic Leukemia
  • a method of treating leukemia or other cancer includes administering to a patient diagnosed with the leukemia or other cancer a regimen that includes periodic doses of a combination of emodin and digoxin.
  • the treatment method may include periodic doses including approximately 5 ug/ml or 10 ug/ml or more of Emodin, along with respectively 0.05 ug/ml or 0.10 ug/ml or more of digoxin.
  • Other combinations may be used in the treatment, including combining 5 ug/ml or more of emodin with at least approximately 0.10 ug/ml digoxin, or at least approximately 10 ug/ml emodin with at least approximately 0.10 ug/ml digoxin, or more than 5 ug/ml of emodin with at least approximately 0.05 ug/ml digoxin, or at least approximately 10 ug/ml emodin and at least approximately 0.05 ug/ml digoxin.
  • Other combinations may be used and prescribed by physicians depending on factors such variances in weight, age, gender, family or patient history, or other characteristics specific to patients.
  • the treatment regimen may include once or twice daily doses, or two or more weekly doses weekly or otherwise. Doses may be taken more than once or twice a day, while the amounts of each dose would be determined according to the periodicity of the treatments.
  • Methods of preparing leukemia or other cancer treatment medicines including preparing a cocktail including a combination of emodin and digoxin.
  • a leukemia or other cancer treatment medicine including a cocktail including a combination of emodin and digoxin.
  • the present invention is directed to novel therapeutic applications of cardiac glycosides such as digoxin and quabain alone or in combination with Emodin and its analogs for the treatment of cancer. More specifically blood cancers. Unexpectedly, the present invention discloses, for the first time, that digoxin synergize with emodin to stimulate cancer cell death.
  • FIG. 1 illustrates the effect of on proliferation of digoxin, Emodin, and their combination on NB4 leukemic cells.
  • the results represent average of triplicates ⁇ STDEV.
  • the percentage of life and death cells was done using staining for PI for death cells and the number of lived cells was determined by FACS.
  • FIG. 2 illustrates the effect of on proliferation of digoxin, Emodin, and their combination on HL-60 leukemic cells.
  • the results represent average of triplicates ⁇ STDEV.
  • the percentage of life and death cells was done using staining for PI for death cells and the number of lived cells was determined by FACS.
  • FIG. 3 illustrates the effect of on proliferation of digoxin, Emodin, and their combination on Jurkat T cell leukemic cells. The results represent average of triplicates ⁇ STDEV. The percentage of life and death cells was done using staining for PI for death cells and the number of lived cells was determined by FACS.
  • FIG. 4 illustrates the effect of on proliferation of digoxin, Emodin, and their combination on HT29 colon cancer cells.
  • the results represent average of triplicates ⁇ STDEV.
  • the percentage of life and death cells was done using staining for PI for death cells and the number of lived cells was determined by FACS.
  • FIG. 5 illustrates the effect of on proliferation of digoxin, Emodin, and their combination on PC3 prostate tumor cells.
  • the results represent average of triplicates ⁇ STDEV.
  • the percentage of life and death cells was done using staining for PI for death cells and the number of lived cells was determined by FACS.
  • FIG. 6 illustrates the effect of proliferation of digoxin, Emodin and their combination on MDA 435 are cell line of Breast Cancer. In the in vitro experiments, there is a dependency on concentration.
  • FIG. 7 illustrates the effect of proliferation of digoxin, Emodin and their combination on MDA 435 are cell lines of Melanoma and Breast Cancer. In this case, concentration of 1/100 had no effect (same as Control) 1 ⁇ 3 had good effect and 1/10 killed all cells. Normal cells were affected 50-90% less than the rate of pathological cells.
  • FIG. 8 illustrates the effect of proliferation of digoxin, Emodin and their combination on Heparanase activity.
  • Heparanase is an enzyme that relates to angiogenesis (the physiological process involving the growth of new blood vessels from pre-existing vessels). This slide depicts the fact that the proliferation of the combination of digoxin and Emodin delays the activity of this enzyme.
  • FIG. 9 illustrates the effect of proliferation of digoxin, Emodin and their combination on HMVEC which is also an enzyme that is related to angiogenesis.
  • FIGS. 10 and 11 illustrate the effect of proliferation of digoxin, Emodin and their combination on NB-4 is Cell Line for AML (Acute Milo Leukemia).
  • the two left bars in the diagram of FIG. 10 are Control (DMSO as well).
  • the Digoxin alone 0.1 ug/ml (illustrated by the 3rd bar) shows a strong effect.
  • Emodin alone has an effect only in large concentration (approximately 10 ug/ml or more).
  • the three bars to the right in FIG. 10 are the effect of the combination of Digoxin and Emodin. Taking Digoxin 0.1 ug/ml and Emodin 10 ug/ml has a very strong effect better than either of the two acting alone.
  • FIGS. 12-13 show that for HL-60, which is Promyolitic Leukemia, as well as for Jurkat, which is Acute T cell Leukemia, the same surprisingly advantageous synergistic effect was observed.
  • FIG. 14 also shows a synergistic advantage of using the combination of Digoxin and Emodin on the HT-29 cell line.
  • the embodiments of the present invention are directed to advantageous medicines and methods of treatment and preparation of medicines and treatments for cancer wherein combinations of digoxin “D” and emodin “E” are used to inhibit tumor cell growth.
  • CXCR4 antagonists on the survival of NB4, HL60, Jurkat leukemic cells and HT29 colon cancer and prostate tumor cells was examined.
  • Digoxin significantly inhibited the growth of leukemic cells at concentrations between (0.05-to 1 microgram/ml).
  • Emodin by itself inhibited the growth of leukemic cells only at concentration upper than 5 microgrm/ml.
  • Combination of digoxin at concentration of 0.1 microgram/and either 5 or 10 microgram/ml of emodin increased significantly the tumor killing ability of both compounds.
  • Digoxin, Emodin, and their combination also add partial however significant effect on HT29 tumor cells.
  • PI-negative cells in culture was determined by FACScalibur analysis (Becton Dickinson Immunocytometry Systems), using CellQuest software.
  • Adherent prostate cancer PC3 cells and colon cancer HT29 cells were seeded at 1 ⁇ 105 viable cells/1 ml per well into a 24-well plate under conditions described above, and following 24-hours exposure to digoxin, Emodin, and their combination, the cells were harvested, washed with PBS and stained with PI and counted as described for hematopoietic cells.
  • the therapeutic index of digoxin is understood to be between 0.125 m′′ g to 0.5 m′′ g, while the LD50 values of emodin in mice are understood to be 0.56 g/k′′ g.
  • the current treatment may be prepared as a mixture of herbs that are known to have separately digoxin “D” and emodin “E”.
  • Aloe-emodin is a natural anthraquinone compound that is present in some traditional medicinal plants such as Rhei Rhizoma and Rheum palmatum. Interestingly, aloe-emodin has been found to have lesser cytotoxicity towards the normal human cells. In-vitro tests with D&E molecules synthesized have been performed on a cell-line. The in-vitro with the plants was similar to the one with the isolated molecules.
  • Emodin may be extracted from “traditional medicinal plants such as Rhei Rhizoma and Rheum Palmatum.”
  • the source of Emodin used is Da Huang—Chinese name, or Rhubarb Root—English name, or Rheum Plamatum—Botanical name, or Radix Rhisoma Rhei—Pharmaceutical name.
  • Emodin may be extracted from Rhubarb, Buckthorn and/or Japanese Knotweed (Fallopia Japonica).
  • Aloe-emodin may be used which is a variety of emodin found in Socotrine, Barbados, and Zanzibar aloes.
  • a medicinal cancer treatment using Emodin is prepared in certain embodiments by mixing the herb in water at a ratio of approximately 10:1.
  • the herb may be ground to a fine powder.
  • the water may be added to the fine powdered herb, and the pot covered.
  • the heat is lowered in certain embodiments to about 70 degrees centigrade.
  • the acqueous mixture is cooked for another hour.
  • the liquid is then strained into a container. In some cases, this may be done twice. In the second cooking, the ratio may be reduced to 7.5:1.
  • the second cooking may take about 45 minutes including the boiling.
  • the source of Digoxin in certain embodiments is Sheng Di Huang—Chinese name, or Foxglove root—English name, or Radix Rhemania—Pharmaceutical name.
  • the preparation of the Digoxin may the same as for the Emodin.
  • the herbs from which the Emodin and Digoxin are extracted are cooked together.
  • Digoxin may be extracted from Digitalis Purpurea or Purple Foxglove.
  • Both harvested non adherent human hematopoietic cancer cell lines NB4 (AML), HL60 and Jurkat, cells were seeded at 2 ⁇ 105 viable cells/1 ml per well into a 24-well plate in triplicates in a medium supplemented with 10% FCS and incubated with different concentrations of digoxin, Emodin, and their combination for 24 hours. Following the incubation, the cells were stained with propidium iodide (PI) (Sigma, St. Louis, Mo.) and percent of viable PI-negative cells in culture was determined by FACScalibur analysis (Becton Dickinson Immunocytometry Systems), using CellQuest software.
  • PI propidium iodide
  • Adherent prostate cancer PC3 cells and colon cancer HT29 cells were seeded at 1 ⁇ 105 viable cells/1 ml per well into a 24-well plate under conditions described above, and following 24-hours exposure to digoxin, Emodin, and their combination, the cells were harvested, washed with PBS and stained with PI and counted as described for hematopoietic cells.
  • the cancer treatment including administering a cocktail including a combination of emodin and digoxin may be combined with other treatments such as may be understood by those skilled in the art and/or as may be described in literature which are hereby incorporated by reference as disclosing alternative embodiments and compounds that may be combined with an emodin, digoxin cocktail in an effective cancer therapy.
  • Emodin and Digoxin may be provided to treat other ailments such as psoriasis and inflammatory disease.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A method and medicine for treating leukemia or other cancer includes administering to a patient diagnosed with leukemia or other cancer a treatment regimen that includes periodic doses of a combination of emodin and digoxin.

Description

    PRIORITY
  • This application is a Division of U.S. patent application Ser. No. 13/018,435, filed Feb. 1, 2011, which claims the benefit of priority to U.S. provisional patent application No. 61/413,430, filed Nov. 13, 2010, which is hereby incorporated by reference.
    • BACKGROUND OF THE INVENTION
  • 1. Field of the Invention
  • The present invention relates generally to cancer therapeutics. More specifically it concerns the use of cardiac glycosides such as Digoxin and Quabain in combination with Emodin and its analogs for the treatment of cancer.
  • 2. Description of the Related Art
  • Herbal medicines are still prevalent, and serve the medicinal needs of a large population around the world. The global herbal medicine market is currently worth around $30 billion. 1 There is an increased effort for the isolation of bioactive phytochemicals from herbs for their possible usefulness in the control of various ailments. Determining molecular structure and mechanisms of action of bioactive phytochemicals are equally important for providing the evidence for their efficacy as well as herbal preparations, which could also potentially lead to the pharmaceutical development of synthetic or semi-synthetic drugs.2View Record in ScopusCited By in Scopus (28)2 About herbal medicines in cancer studies, several previous studies demonstrate that certain phytochemicals present in medicinal herbs exert anti-cancer activities. Among three structurally related anthraquinones, including emodin, physcion, and chrysophanol, emodin showed the most potent cytotoxic effects on tumor cells. Emodin (1,3,8-trihydroxy-6-methylanthraquinone) and aloe-emodin, 1,8-dihydroxy-3-hydroxymethyl-9,10-anthracenedione as shown a chemotherapeutic activity in vitro and in animal models for the treatment of various types of cancers, including bladder cancer,3 lung cancer,4 and hepatoma.5, and leukemia. Aloe-emodin is a natural anthraquinone compound that is present in some traditional medicinal plants such as Rhei Rhizoma and Rheum palmatum, Interestingly, aloe-emodin has been found to have lesser cytotoxicity towards the normal human cells.6
  • Plant-derived cardiac glycosides such as digoxin are used for the treatment of congestive heart failure and other cardiac disorders (1). Their main pharmacologic actions are mediated through inhibition of the sodium pump, Na+- and K+-dependent ATPase (NKA) 1 (EC 3.6.3.9) (2). NKA, a ubiquitous membrane cationic transporter protein, controls normal membrane potential in all eukaryotic cells by maintaining high K+ and low Na+ concentrations. It consists of a catalytic subunit and a B glycoprotein subunit (3). Studies have suggested that plant-derived cardiac glycosides regulate some cellular processes, such as proliferation and apoptosis, in a variety of cancer cells (4)(5)(6)(7).
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 illustrates the effect of on proliferation of digoxin, Emodin, and their combination on NB4 leukemic cells.
  • FIG. 2 illustrates the effect of on proliferation of digoxin, Emodin, and their combination on HL-60 leukemic cells.
  • FIG. 3 illustrates the effect of on proliferation of digoxin, Emodin, and their combination on Jurkat T cell leukemic cells.
  • FIG. 4 illustrates the effect of on proliferation of digoxin, Emodin, and their combination on HT29 colon cancer cells.
  • FIG. 5 illustrates the effect of proliferation of digoxin, Emodin, and their combination on PC3 prostate tumor cells.
  • FIG. 6 illustrates the effect of proliferation of Digoxin, Emodin and their combination on MDA 435 Breast Cancer cells.
  • FIG. 7 illustrates the effect of proliferation of Digoxin, Emodin and their combination on MDA 435 cell lines of Melanoma and Breast Cancer.
  • FIG. 8 illustrates the effect of proliferation of Digoxin, Emodin and their combination on Heparanase activity.
  • FIG. 9 illustrates the effect of proliferation of Digoxin, Emodin and their combination on HMVEC activity.
  • FIGS. 10-11 illustrates the effect of proliferation of Digoxin, Emodin and their combination on NB-4 Cell Line for AML (Acute Milo Leukemia).
  • FIG. 12 illustrates the effect of proliferation of Digoxin, Emodin and their combination on HL-60 Cell Line.
  • FIG. 13 illustrates the effect of proliferation of Digoxin, Emodin and their combination on Jurkat cell line.
  • FIG. 14 illustrates the effect of proliferation of Digoxin, Emodin and their combination on HT-29 cell line.
    •  INCORPORATION BY REFERENCE
  • What follows is a cite list of references which are, in addition to those references cited above and below herein, and including that which is described as background, the invention summary, brief description of the drawings, the drawings and the abstract, hereby incorporated by reference into the detailed description of the preferred embodiments below, as disclosing alternative embodiments of elements or features of the preferred embodiments not otherwise set forth in detail below. A single one or a combination of two or more of these references may be consulted to obtain a variation of the preferred embodiments described in the detailed description below. Further patent, patent application and non-patent references are cited in the written description and are also incorporated by reference into the preferred embodiment with the same effect as just described with respect to the following references:
  • U.S. Pat. Nos. 5,872,103, 6,197,754, 6,740,665, 6,812,255, 7,268,162, 7,358,222, 7,381,535, 7,393,656, 7,563,584, 7,695,926, 7,790,905, and United States published applications no. 2003/0211180, 2005/0026849, 2005/0196473, 2006/0205679, 2007/0191262, 2008/0152700, 2008/0220441, 2009/0018088, 2009/0143279, 2009/0215042, 2009/0269772, 2010/0068198, 2010/0092585, 2010/0144647, 2010/0167286; and
  • PCT and foreign published applications no. WO01/66123, WO2004/052294, WO2006/053049, WO2007/130124; RU2008107585; MX2010005081; KR100221762; CN01362702; CN1370587; and
  • Citations: Chronic Lymphocytic Leukemia by the Leukemia & Lymphoma Society, Medifocus.com Medifocus Guide on Chronic Lymphocytic Leukemia;
  • RANJIT THOMAS, et al., Spontaneous Clinical Regression in Chronic Lymphocytic Leukemia, British Journal of Haematology, 2002, 116, 341-345;
  • DRAGOMIR MARISAVLJEVIC, et al., Spontaneous Clinical Remission of Chronic Lymphocytic Leukemia, Haema 2003; 6(3): 394-397;
  • UPSHAW J D, Jr., et al., Spontaneous Remission of B cell Chronic Lymphocytic Leukemia associated with T Lymphocytic Hyperplasia in bone marrow, South Med J. 2002 June 1995(6): 647-9;
  • WIERNIK P H, Second neoplasms in patients with chronic lymphocytic leukemia, Current Treat Options Oncol. 2004 June; 5(3):215-23;
  • LUIS FAYAD, M.D. and SUSAN O'BRIEN, M.D., Chronic Lymphocytic Leukemia and Associated Disorders, Medical Oncology: A Comprehensive Review, 1995;
  • MICHAEL J. KEATING, et al., Biology and Treatment of Chronic Lymphocytic Leukemia, American Society of Hematology, Hematology 2003, 153-175;
  • GE MARTI, et al., Descriptive Epidemiology of Chronic Lymphocytic Leukemia (CLL).
    • DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
  • A method of treating leukemia or other cancer is provided. The treatment includes administering to a patient diagnosed with the leukemia or other cancer a regimen that includes periodic doses of a combination of emodin and digoxin.
  • The treatment method may include periodic doses including approximately 5 ug/ml or 10 ug/ml or more of Emodin, along with respectively 0.05 ug/ml or 0.10 ug/ml or more of digoxin. Other combinations may be used in the treatment, including combining 5 ug/ml or more of emodin with at least approximately 0.10 ug/ml digoxin, or at least approximately 10 ug/ml emodin with at least approximately 0.10 ug/ml digoxin, or more than 5 ug/ml of emodin with at least approximately 0.05 ug/ml digoxin, or at least approximately 10 ug/ml emodin and at least approximately 0.05 ug/ml digoxin. Other combinations may be used and prescribed by physicians depending on factors such variances in weight, age, gender, family or patient history, or other characteristics specific to patients.
  • The treatment regimen may include once or twice daily doses, or two or more weekly doses weekly or otherwise. Doses may be taken more than once or twice a day, while the amounts of each dose would be determined according to the periodicity of the treatments.
  • Methods of preparing leukemia or other cancer treatment medicines are also provided, including preparing a cocktail including a combination of emodin and digoxin.
  • A leukemia or other cancer treatment medicine is also provided, including a cocktail including a combination of emodin and digoxin.
  • The present invention is directed to novel therapeutic applications of cardiac glycosides such as digoxin and quabain alone or in combination with Emodin and its analogs for the treatment of cancer. More specifically blood cancers. Unexpectedly, the present invention discloses, for the first time, that digoxin synergize with emodin to stimulate cancer cell death.
  • FIG. 1 illustrates the effect of on proliferation of digoxin, Emodin, and their combination on NB4 leukemic cells. The results represent average of triplicates±STDEV. The percentage of life and death cells was done using staining for PI for death cells and the number of lived cells was determined by FACS.
  • FIG. 2 illustrates the effect of on proliferation of digoxin, Emodin, and their combination on HL-60 leukemic cells. The results represent average of triplicates±STDEV. The percentage of life and death cells was done using staining for PI for death cells and the number of lived cells was determined by FACS.
  • FIG. 3 illustrates the effect of on proliferation of digoxin, Emodin, and their combination on Jurkat T cell leukemic cells. The results represent average of triplicates±STDEV. The percentage of life and death cells was done using staining for PI for death cells and the number of lived cells was determined by FACS.
  • FIG. 4 illustrates the effect of on proliferation of digoxin, Emodin, and their combination on HT29 colon cancer cells. The results represent average of triplicates±STDEV.
  • The percentage of life and death cells was done using staining for PI for death cells and the number of lived cells was determined by FACS.
  • FIG. 5 illustrates the effect of on proliferation of digoxin, Emodin, and their combination on PC3 prostate tumor cells. The results represent average of triplicates±STDEV. The percentage of life and death cells was done using staining for PI for death cells and the number of lived cells was determined by FACS.
  • FIG. 6 illustrates the effect of proliferation of digoxin, Emodin and their combination on MDA 435 are cell line of Breast Cancer. In the in vitro experiments, there is a dependency on concentration.
  • FIG. 7 illustrates the effect of proliferation of digoxin, Emodin and their combination on MDA 435 are cell lines of Melanoma and Breast Cancer. In this case, concentration of 1/100 had no effect (same as Control) ⅓ had good effect and 1/10 killed all cells. Normal cells were affected 50-90% less than the rate of pathological cells.
  • FIG. 8 illustrates the effect of proliferation of digoxin, Emodin and their combination on Heparanase activity. Heparanase is an enzyme that relates to angiogenesis (the physiological process involving the growth of new blood vessels from pre-existing vessels). This slide depicts the fact that the proliferation of the combination of digoxin and Emodin delays the activity of this enzyme.
  • FIG. 9 illustrates the effect of proliferation of digoxin, Emodin and their combination on HMVEC which is also an enzyme that is related to angiogenesis.
  • FIGS. 10 and 11 illustrate the effect of proliferation of digoxin, Emodin and their combination on NB-4 is Cell Line for AML (Acute Milo Leukemia). The two left bars in the diagram of FIG. 10 are Control (DMSO as well). The Digoxin alone 0.1 ug/ml (illustrated by the 3rd bar) shows a strong effect. Emodin alone has an effect only in large concentration (approximately 10 ug/ml or more). The three bars to the right in FIG. 10 are the effect of the combination of Digoxin and Emodin. Taking Digoxin 0.1 ug/ml and Emodin 10 ug/ml has a very strong effect better than either of the two acting alone. In fact, the effect is more than double with 892 live cells measured when Emodin alone is used, and 892 when Digoxin alone is used, and 371 were measured when both Digoxin and Emodin were used in combination. This surprising effect of the combination of Digoxin and Emodin shows an advantageous feature of the present invention.
  • FIGS. 12-13 show that for HL-60, which is Promyolitic Leukemia, as well as for Jurkat, which is Acute T cell Leukemia, the same surprisingly advantageous synergistic effect was observed.
  • FIG. 14 also shows a synergistic advantage of using the combination of Digoxin and Emodin on the HT-29 cell line.
    • EXAMPLES
  • The embodiments of the present invention are directed to advantageous medicines and methods of treatment and preparation of medicines and treatments for cancer wherein combinations of digoxin “D” and emodin “E” are used to inhibit tumor cell growth. The effect of CXCR4 antagonists on the survival of NB4, HL60, Jurkat leukemic cells and HT29 colon cancer and prostate tumor cells was examined. Digoxin significantly inhibited the growth of leukemic cells at concentrations between (0.05-to 1 microgram/ml). Emodin by itself inhibited the growth of leukemic cells only at concentration upper than 5 microgrm/ml. Combination of digoxin at concentration of 0.1 microgram/and either 5 or 10 microgram/ml of emodin increased significantly the tumor killing ability of both compounds. Digoxin, Emodin, and their combination also add partial however significant effect on HT29 tumor cells.
  • The effect of the effect of on proliferation of digoxin, Emodin, and their combination on the viability of cancer cell lines from different origin was studied. Harvested non adherent human hematopoietic cancer cell lines NB4, HL60 and Jurkat, cells were seeded at 2×105 viable cells/1 ml per well into a 24-well plate in triplicates in a medium supplemented with 10% FCS and incubated with different concentrations of digoxin, Emodin, and their combination for 24 hours. Following the incubation, the cells were stained with propidium iodide (PI) (Sigma, St. Louis, Mo.) and percent of viable PI-negative cells in culture was determined by FACScalibur analysis (Becton Dickinson Immunocytometry Systems), using CellQuest software. Adherent prostate cancer PC3 cells and colon cancer HT29 cells were seeded at 1×105 viable cells/1 ml per well into a 24-well plate under conditions described above, and following 24-hours exposure to digoxin, Emodin, and their combination, the cells were harvested, washed with PBS and stained with PI and counted as described for hematopoietic cells.
  • The therapeutic index of digoxin is understood to be between 0.125 m″ g to 0.5 m″ g, while the LD50 values of emodin in mice are understood to be 0.56 g/k″ g.
  • When combining D and E in accordance with the present invention, there is a surprising and unexpected symbiotic effect.
  • The current treatment may be prepared as a mixture of herbs that are known to have separately digoxin “D” and emodin “E”. Aloe-emodin is a natural anthraquinone compound that is present in some traditional medicinal plants such as Rhei Rhizoma and Rheum palmatum. Interestingly, aloe-emodin has been found to have lesser cytotoxicity towards the normal human cells. In-vitro tests with D&E molecules synthesized have been performed on a cell-line. The in-vitro with the plants was similar to the one with the isolated molecules.
  • Emodin may be extracted from “traditional medicinal plants such as Rhei Rhizoma and Rheum Palmatum.” In one embodiment, the source of Emodin used is Da Huang—Chinese name, or Rhubarb Root—English name, or Rheum Plamatum—Botanical name, or Radix Rhisoma Rhei—Pharmaceutical name. Emodin may be extracted from Rhubarb, Buckthorn and/or Japanese Knotweed (Fallopia Japonica). Aloe-emodin may be used which is a variety of emodin found in Socotrine, Barbados, and Zanzibar aloes.
  • A medicinal cancer treatment using Emodin is prepared in certain embodiments by mixing the herb in water at a ratio of approximately 10:1. The herb may be ground to a fine powder. The water may be added to the fine powdered herb, and the pot covered. After boiling, the heat is lowered in certain embodiments to about 70 degrees centigrade. The acqueous mixture is cooked for another hour. The liquid is then strained into a container. In some cases, this may be done twice. In the second cooking, the ratio may be reduced to 7.5:1. The second cooking may take about 45 minutes including the boiling.
  • The source of Digoxin in certain embodiments is Sheng Di Huang—Chinese name, or Foxglove root—English name, or Radix Rhemania—Pharmaceutical name. The preparation of the Digoxin may the same as for the Emodin. In certain embodiments, the herbs from which the Emodin and Digoxin are extracted are cooked together. Digoxin may be extracted from Digitalis Purpurea or Purple Foxglove.
  • Both harvested non adherent human hematopoietic cancer cell lines NB4 (AML), HL60 and Jurkat, cells were seeded at 2×105 viable cells/1 ml per well into a 24-well plate in triplicates in a medium supplemented with 10% FCS and incubated with different concentrations of digoxin, Emodin, and their combination for 24 hours. Following the incubation, the cells were stained with propidium iodide (PI) (Sigma, St. Louis, Mo.) and percent of viable PI-negative cells in culture was determined by FACScalibur analysis (Becton Dickinson Immunocytometry Systems), using CellQuest software. Adherent prostate cancer PC3 cells and colon cancer HT29 cells were seeded at 1×105 viable cells/1 ml per well into a 24-well plate under conditions described above, and following 24-hours exposure to digoxin, Emodin, and their combination, the cells were harvested, washed with PBS and stained with PI and counted as described for hematopoietic cells.
  • The cancer treatment including administering a cocktail including a combination of emodin and digoxin may be combined with other treatments such as may be understood by those skilled in the art and/or as may be described in literature which are hereby incorporated by reference as disclosing alternative embodiments and compounds that may be combined with an emodin, digoxin cocktail in an effective cancer therapy.
  • It is also believed that treatment with an advantageous combination of Emodin and Digoxin may be provided to treat other ailments such as psoriasis and inflammatory disease.
  • While the invention has been described in terms of several embodiments, those skilled in the art will recognize that the invention is not limited to the embodiments described, but can be practiced with modification and alteration within the spirit and scope of the appended claims. The description is thus to be regarded as illustrative instead of limiting of the invention as set forth in the appended claims including structural and functional equivalents thereof.
  • While an exemplary drawing and specific embodiments of the present invention have been described and illustrated, it is to be understood that that the scope of the present invention is not to be limited to the particular embodiments discussed. Thus, the embodiments shall be regarded as illustrative rather than restrictive, and it should be understood that variations may be made in those embodiments by workers skilled in the arts without departing from the scope of the present invention, as set forth in the claims below and structural and functional equivalents thereof.
  • In addition, in methods that may be performed according to preferred embodiments herein and that may have been described above, the operations have been described in selected typographical sequences. However, the sequences have been selected and so ordered for typographical convenience and are not intended to imply any particular order for performing the operations, unless expressly set forth or understood by those skilled in the art being necessary.

Claims (20)

What is claimed is:
1. A method of preparing medicine for treating leukemia, melanoma, or colon, prostate or breast cancer, comprising preparing a combination including an effective amount of digoxin with 5 ug/ml or more of emodin.
2. The method of claim 1, wherein the combination comprises approximately 10 g/ml or more of emodin.
3. The method of claim 1, wherein the combination comprises approximately 0.05 ug/ml or more of digoxin.
4. The method of claim 1, wherein the combination comprises approximately 0.10 ug/ml or more of digoxin.
5. The method of claim 1, wherein the combination comprises approximately 10 ug/ml or more of emodin and approximately 0.10 ug/ml or more of digoxin.
6. The method of claim 1, wherein the combination comprises approximately 10 ug/ml or more of emodin and approximately 0.05 ug/ml or more of digoxin.
7. The method of claim 1, comprising preparing an aqueous solution including cooking emodin- and digoxin-containing herbs in water.
8. The method of claim 1, comprising extracting the emodin from rhubarb root.
9. The method of claim 1, comprising extracting the emodin from rhubarb.
10. The method of claim 1, comprising extracting the emodin from Buckthorn.
11. The method of claim 1, comprising extracting the emodin from Japanese Knotweed.
12. A medicine for treating leukemia, melanoma, or colon, prostate or breast cancer, comprising a combination of an effective amount of digoxin with approximately 5 ug/ml or more of emodin.
13. The medicine of claim 12, comprising approximately 10 g/ml or more of emodin.
14. The medicine of claim 12, comprising approximately 0.05 ug/ml or more of digoxin.
15. The medicine of claim 12, comprising approximately 0.1 ug/ml or more of digoxin.
16. The medicine of claim 12, comprising approximately 10 ug/ml or more of emodin and approximately 0.10 ug/ml or more of digoxin.
17. The medicine of claim 12, comprising approximately 10 g/ml or more of emodin and approximately 0.05 ug/ml or more of digoxin.
18. The medicine of claim 12, comprising a pharmaceutically acceptable carrier.
19. The medicine of claim 18, wherein the carrier comprises water.
20. The medicine of claim 18, wherein the carrier comprises DMSO.
US14/034,423 2010-11-13 2013-09-23 Cardiac Glycoside Analogs in Combination with Emodin for Cancer Therapy Abandoned US20140206631A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/034,423 US20140206631A1 (en) 2010-11-13 2013-09-23 Cardiac Glycoside Analogs in Combination with Emodin for Cancer Therapy

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41343010P 2010-11-13 2010-11-13
US13/018,435 US8541382B2 (en) 2010-11-13 2011-02-01 Cardiac glycoside analogs in combination with emodin for cancer therapy
US14/034,423 US20140206631A1 (en) 2010-11-13 2013-09-23 Cardiac Glycoside Analogs in Combination with Emodin for Cancer Therapy

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US13/018,435 Division US8541382B2 (en) 2010-11-13 2011-02-01 Cardiac glycoside analogs in combination with emodin for cancer therapy

Publications (1)

Publication Number Publication Date
US20140206631A1 true US20140206631A1 (en) 2014-07-24

Family

ID=46048345

Family Applications (2)

Application Number Title Priority Date Filing Date
US13/018,435 Expired - Fee Related US8541382B2 (en) 2010-11-13 2011-02-01 Cardiac glycoside analogs in combination with emodin for cancer therapy
US14/034,423 Abandoned US20140206631A1 (en) 2010-11-13 2013-09-23 Cardiac Glycoside Analogs in Combination with Emodin for Cancer Therapy

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US13/018,435 Expired - Fee Related US8541382B2 (en) 2010-11-13 2011-02-01 Cardiac glycoside analogs in combination with emodin for cancer therapy

Country Status (4)

Country Link
US (2) US8541382B2 (en)
EP (1) EP2637671A4 (en)
JP (1) JP5961622B2 (en)
WO (1) WO2012063134A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9066974B1 (en) 2010-11-13 2015-06-30 Sirbal Ltd. Molecular and herbal combinations for treating psoriasis
US9095606B1 (en) 2010-11-13 2015-08-04 Sirbal Ltd. Molecular and herbal combinations for treating psoriasis
WO2017019651A1 (en) 2015-07-29 2017-02-02 Sirbal Ltd. Herbal combinations for treating psoriasis

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8541382B2 (en) 2010-11-13 2013-09-24 Sirbal Ltd. Cardiac glycoside analogs in combination with emodin for cancer therapy
US9561245B2 (en) 2012-09-06 2017-02-07 The Board Of Regents Of The University Of Texas System Combination treatments for melanoma
US20140080772A1 (en) * 2012-09-06 2014-03-20 The Board Of Regents Of The University Of Texas System Treatments for melanoma
US9572828B2 (en) * 2013-07-18 2017-02-21 The Board Of Regents Of The University Of Texas System Treatment for melanoma
EP3586858A1 (en) 2015-10-01 2020-01-01 Photodynamic Inc. Novel polygonum cuspidatum extracts and their use as photodynamic inactivating agents
US9795570B2 (en) * 2016-03-17 2017-10-24 University Of South Carolina Modulation of macrophage phenotype by emodin
US20240076666A1 (en) * 2021-02-12 2024-03-07 The Regents Of The University Of California Immunomodulators Targeting MORC3 for Interferon Induction
JP2023086330A (en) * 2021-12-10 2023-06-22 株式会社アミノエース Composition for inhibiting proliferation of cancer cells

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2068027A (en) * 1935-05-09 1937-01-19 Rare Chemicals Inc Process of making glucosides from digitalis purpurea
SG60053A1 (en) * 1997-04-10 1999-02-22 Chang Teh Shan Herb composition and an herbal plaster made from the same
US20020164387A1 (en) * 2001-02-12 2002-11-07 Kaiyuan Wei Herbal composition and method for controlling body weight and composition
WO2004052294A2 (en) * 2002-12-06 2004-06-24 Board Of Regents, The University Of Texas System Compositions and methods related to lipid:emodin formulations
WO2007130124A1 (en) * 2006-05-09 2007-11-15 Unversity Of Louisville Research Foundation Treating cancer with cardiac glycosides
US8541382B2 (en) * 2010-11-13 2013-09-24 Sirbal Ltd. Cardiac glycoside analogs in combination with emodin for cancer therapy
US8597695B1 (en) * 2010-11-13 2013-12-03 Sirbal Ltd. Herbal combinations for treatment of a skin condition

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5872103A (en) 1986-11-26 1999-02-16 Belletti; Dino A. Prevention of mammary tumors by treatment with cardiac glycosides
JPH06321795A (en) 1993-05-07 1994-11-22 Kuga Takaaki Medicine for treating dermatosis such as atopic dermatosis
US6326356B1 (en) 1996-10-18 2001-12-04 Board Of Regents, The University Of Texas System Suppression of neu overexpression using a mini-E1A gene
WO1997027848A1 (en) * 1996-01-31 1997-08-07 Board Of Regents, The University Of Texas System SENSITIZATION OF HER2/neu OVER-EXPRESSING CANCER CELLS TO CHEMOTHERAPEUTIC DRUGS
KR100221762B1 (en) 1996-10-29 1999-09-15 이승기 Use of emodin as an anticancer agent
AU760766B2 (en) 1998-08-18 2003-05-22 Regents Of The University Of California, The Preventing airway mucus production by administration of EGF-R antagonists
US6740665B1 (en) 1999-02-10 2004-05-25 Ramachandran Murali Tyrosine kinase inhibitors and methods of using the same
ES2358639T3 (en) 2000-03-09 2011-05-12 Yale University COMPOSITION THAT CONSISTS OF PHY906 AND CHEMOTHERAPEUTIC AGENTS.
US7534455B2 (en) 2000-03-09 2009-05-19 Yale University Herbal composition PHY906 and its use in chemotherapy
IT1318547B1 (en) 2000-05-31 2003-08-27 Giorgio Palu USE OF ALOE-EMODIN IN THE TREATMENT OF NEOPLASTIC DIORIGINAL NEUROECTODERMAL DISEASES.
US20030125265A1 (en) * 2001-05-09 2003-07-03 Mien-Chie Hung Anti-estrogen receptor agents for chemotherapy
ITMI20010957A1 (en) 2001-05-10 2002-11-10 Giorgio Palu AOE-HEMODINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PATHOLOGIENEOPLASTICS
US20080220441A1 (en) 2001-05-16 2008-09-11 Birnbaum Eva R Advanced drug development and manufacturing
AU2002365421A1 (en) 2001-07-10 2003-09-02 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for detecting the activation state of the multiple proteins in single cells
US7381535B2 (en) 2002-07-10 2008-06-03 The Board Of Trustees Of The Leland Stanford Junior Methods and compositions for detecting receptor-ligand interactions in single cells
US7695926B2 (en) 2001-07-10 2010-04-13 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for detecting receptor-ligand interactions in single cells
US7393656B2 (en) 2001-07-10 2008-07-01 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for risk stratification
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
CN1370587A (en) 2002-03-05 2002-09-25 王舒妍 Prepn of aloe gel
US20050026849A1 (en) 2003-03-28 2005-02-03 Singh Chandra U. Water soluble formulations of digitalis glycosides for treating cell-proliferative and other diseases
US20060229267A1 (en) 2004-06-01 2006-10-12 Reza Sheikhnejad Methods and compositions for the inhibition of gene expression
US20060205679A1 (en) 2004-10-22 2006-09-14 Azaya Therapeutics, Inc. Topical and oral formulations of cardiac glycosides for treating skin diseases
CN1796400B (en) 2004-12-29 2010-06-23 杭州浙大力夫生物科技有限公司 Extractive of phytosterol extracted from bamboo shoot, preparation method and application
EP1891218A2 (en) 2005-06-08 2008-02-27 Compugen Ltd. Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
US20070191262A1 (en) 2005-11-15 2007-08-16 University Of Iowa Research Foundation Cancer Therapy and Prevention Based on Modulation of Complement activity
US20090018088A1 (en) 2006-10-27 2009-01-15 University Of Louisville Research Foundation Treating cancer with cardiac glycosides
AU2006350507A1 (en) 2006-11-09 2008-05-15 Unibioscreen S.A. Targeting of alpha-1 or alpha-3 subunit of Na+, K+-ATPase in the treatment of proliferative diseases
CA2678427C (en) 2007-02-16 2016-06-07 Ktb Tumorforschungsgesellschaft Mbh Dual acting prodrugs
WO2008156654A2 (en) 2007-06-15 2008-12-24 Massachusetts Institute Of Technology Cytoskeleton modulators for treating metabolic disorders
RU2571687C2 (en) 2007-11-13 2015-12-20 Феникс Байотекнолоджи Инк. Kit for detecting probability of therapeutic response to anti-cancer chemotherapy with cardiac glycoside
WO2009151511A1 (en) 2008-04-29 2009-12-17 Therasis, Inc. Systems and methods for identifying combinations of compounds of therapeutic interest
US8669048B2 (en) 2008-06-24 2014-03-11 Parkinson's Institute Pluripotent cell lines and methods of use thereof
CN101362702B (en) 2008-09-12 2012-06-20 南昌大学 Emodin derivates and application thereof in anti-cancer medicine preparation
AU2009303460B9 (en) 2008-10-14 2014-12-18 Nerium Biotechnology, Inc. Process for extracting cardiac glycodides and compositions

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2068027A (en) * 1935-05-09 1937-01-19 Rare Chemicals Inc Process of making glucosides from digitalis purpurea
SG60053A1 (en) * 1997-04-10 1999-02-22 Chang Teh Shan Herb composition and an herbal plaster made from the same
US20020164387A1 (en) * 2001-02-12 2002-11-07 Kaiyuan Wei Herbal composition and method for controlling body weight and composition
WO2004052294A2 (en) * 2002-12-06 2004-06-24 Board Of Regents, The University Of Texas System Compositions and methods related to lipid:emodin formulations
WO2007130124A1 (en) * 2006-05-09 2007-11-15 Unversity Of Louisville Research Foundation Treating cancer with cardiac glycosides
US8541382B2 (en) * 2010-11-13 2013-09-24 Sirbal Ltd. Cardiac glycoside analogs in combination with emodin for cancer therapy
US8597695B1 (en) * 2010-11-13 2013-12-03 Sirbal Ltd. Herbal combinations for treatment of a skin condition
US8734859B1 (en) * 2010-11-13 2014-05-27 Sirbal Ltd. Molecular combinations for cancer or other disease treatment

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9066974B1 (en) 2010-11-13 2015-06-30 Sirbal Ltd. Molecular and herbal combinations for treating psoriasis
US9095606B1 (en) 2010-11-13 2015-08-04 Sirbal Ltd. Molecular and herbal combinations for treating psoriasis
WO2017019651A1 (en) 2015-07-29 2017-02-02 Sirbal Ltd. Herbal combinations for treating psoriasis

Also Published As

Publication number Publication date
WO2012063134A2 (en) 2012-05-18
US8541382B2 (en) 2013-09-24
EP2637671A2 (en) 2013-09-18
WO2012063134A3 (en) 2013-12-05
US20120122807A1 (en) 2012-05-17
JP5961622B2 (en) 2016-08-02
JP2014506233A (en) 2014-03-13
EP2637671A4 (en) 2015-01-07

Similar Documents

Publication Publication Date Title
US8541382B2 (en) Cardiac glycoside analogs in combination with emodin for cancer therapy
Ke et al. Advances for pharmacological activities of Polygonum cuspidatum-A review
Chien et al. Salvianolic acid A alleviates ischemic brain injury through the inhibition of inflammation and apoptosis and the promotion of neurogenesis in mice
Singh et al. Emerging importance of dietary phytochemicals in fight against cancer: role in targeting cancer stem cells
Adnan et al. Physcion and physcion 8-O-β-D-glucopyranoside: Natural anthraquinones with potential anticancer activities
Lee et al. Anti-cancer activity of Centipeda minima extract in triple negative breast cancer via inhibition of AKT, NF-κB, and STAT3 signaling pathways
Yu et al. Protective potential of hydroxysafflor yellow A in cerebral ischemia and reperfusion injury: An overview of evidence from experimental studies
Wang et al. Ginsenoside Rg3 attenuates myocardial ischemia/reperfusion injury via Akt/endothelial nitric oxide synthase signaling and the B-cell lymphoma/B-cell lymphoma-associated X protein pathway
Xie et al. Comparation of Anti‐Inflammatory and Antioxidantactivities of Curcumin, Tetrahydrocurcuminand Octahydrocurcuminin LPS‐Stimulated RAW264. 7 Macrophages
Ma et al. Herbal medicines for constipation and phytochemical comparison of active components
Kim et al. Panax notoginseng inhibits tumor growth through activating macrophage to M1 polarization
Zhao et al. Schizandrin B attenuates hypoxia/reoxygenation injury in H9c2 cells by activating the AMPK/Nrf2 signaling pathway
Khalaf et al. Verbascoside—A review of its antitumor activities
Han et al. Anti-metastatic effect and mechanisms of Wenshen Zhuanggu Formula in human breast cancer cells
JP2018538319A (en) Pharmaceutical composition for treating leukemia and method for producing the same
CN102579425B (en) Caulis Spatholobi extract, application thereof and new application of isoliquiritigenin
Xia et al. Pomegranate juice ameliorates pulmonary fibrosis by regulating inflammatory response and epithelial mesenchymal transformation
CN102772611A (en) Traditional Chinese medicine composition and preparation method and application thereof
Xu et al. Fractions of shen-sui-tong-zhi formula enhance osteogenesis via activation of β-catenin signaling in growth plate chondrocytes
Zheng et al. Effect of Panax ginseng combined with Angelica sinensis on the dissolution of ginsenosides and in chemotherapy mice hematopoietic function
Zhu et al. Preliminary study on the in vitro antitumor effects of nidus vespae on gastric cancer
Guan et al. Chrysophanol induces cell apoptosis and suppresses cell invasion by regulating AKT and MAPK signaling pathway in melanoma cells
Adib-Hajbagheri et al. Protective Effects of Ginsenosides on Drug-induced Cardiotoxicity: A New Therapeutic Approach with Focus on Molecular Mechanisms in Cardio-oncology Field
ABDULLAH et al. Combination Effect of Tamoxifen and Ascorbic Acid Treatment on Breast Cancer Cells (MCF-7) and Cervical Cancer Cells (HeLa).
Ni et al. Icariside II: natural occurrence, biotransformation, pharmacological activity, synthetic modification, pharmacokinetics, and bioavailability

Legal Events

Date Code Title Description
AS Assignment

Owner name: SIRBAL LTD., CYPRUS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SHRAIBOM, NADAV;REEL/FRAME:031663/0924

Effective date: 20110402

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION